新藥技術(shù)轉(zhuǎn)讓背景和發(fā)展趨勢(參考版)
2024-10-21 15:54本頁面
【正文】 D, market research, KOLs, reimbursement and regulatory ? Prepare partnering materials and run an efficient process What role does the asset have in corporate development? ? What structure are you looking for? ? Summarize and prepare a 5 minute pitch ? Utilize a top down approach with BD and Ramp。s investors seek liquidity ? Deal activity spiked in the summer of 2021 ? Significant gap exists on valuation of many panies ? Investors asking price ? Buyers perceived value ? Source: Deloitte Pharma / Biotech Biotech / Biotech 73 deals between 202108 ? 38 Public Companies (%) ? 35 Private Companies (%) ? 44 Product Companies (%) ? 29 Platform Companies (%) ? 29 Large Molecule Focus (%) ? 44 Small Molecule Focus (%) ? Average Valuation $1, ? Median Valuation $ ? Total Value $135, 90 deals between 202108 ? 33 Public Companies (%) ? 57 Private Companies (%) ? 72 Product Companies (%) ? 18 Platform Companies (%) ? 22 Large Molecule Focus (%) ? 68 Small Molecule Focus (%) ? Average Valuation $ ? Median Valuation $ ? Total Value $30, Defining BigCorps of BioPharma Licensing Defining the ‘BigCos’ ? Integrated Biopharma panies ? Revenue generating and profitable ? Valuation in excess of $1 billion Top 40 BigCos sign 90% of deals, by total dollar value Biotech Therapeutic Outlicense Deals with BigCorp (2021Q32021) ? 70 distinct BigCorps ? 1,237 alliances ? $139 billion announced total value ? Payments in alliances ($M) Upfront Equity Announced Total ? 202109 Total $12,159 $2,857 $139,238 ? Annual Average
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號-1